The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Mesenchymal stem cells as targeted-delivery vehicles for image-guided cancer treatment


Stanford Reference:

11-366


Abstract


Researchers in Prof. Zhen Cheng’s laboratory have combined a highly efficient gene delivery system with the tumor tropism of mesenchymal stem cells (MSCs) to deliver and express an antineoplastic gene directly to treat cancer, including metastatic tumors. Under normal circumstances, MSCs are recruited to tumors by signals and factors such as VEGF. Once there, they promote the survival and dissemination of tumor cells. This invention exploits the tumor-homing feature of MSCs to therapeutic advantages to target anticancer agents to malignant cells. In addition, this technology utilizes a dual function vector designed to deliver the tumor-fighting payload along with a reporter gene to non-invasively monitor MSC distribution in vivo. This method enables high local concentration of an anti-tumor protein to increase treatment efficacy and decrease toxic systemic side effects.


Decreased tumor growth with in vivo treatment of breast cancer lung metastasis model monitored by bioluminescence imaging. Breast cancer cells were injected day 0. Then mice received no treatment (a), control MSCs (b), or transfected MSCs (c) injected day 7, 14 and 21.

Stage of Research
The inventors have demonstrated this technology in a mouse model of lung metastatic cancer. They were able to reduce tumor growth with minimal side effects and also monitor MSC distribution in real-time with bioluminescence.

Applications


  • Cell-based cancer gene therapy - MSC gene delivery to target tumors, particularly breast cancer lung metastasis
  • Imaging - using a reporter gene, MSC distribution can be monitored by bioluminescence, fluorescence, MRI, or PET scanning

Advantages


  • Improved efficacy - the anti-tumor protein is delivered directly to the site of the tumor using a highly efficient gene delivery technology
  • Reduced side effects - localizing gene delivery is less toxic than if the gene product were administered systemically (mouse studies demonstrated minimal side effects)
  • Dual-function expression system - delivers therapeutic gene product and allows non-invasive real-time monitoring of MSCs

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 5/22/2014
 

Licensing Contact


Gregg Kyle, Senior Licensing Associate
+1-650-725-3476 (Direct)
Login to Request Information

[-] Map/Timeline

97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
99-158 Plasmid DNA vectors that integrate into host chromosomal DNA in vivo [Sleeping Beauty]
00-003 Altered recombinases for genome modification ("Shuffled" recombinases)

more technologies

Related Keywords


bone marrow-derived mesenchymal stem cells   Cancer Gene Therapy   cell-based therapy   Cytotoxic gene therapy   lentiviral   lentivirus   metastatic breast cancer   mesenchymal stem cell   cancer lung metastasis   metastasis   gene delivery   therapeutic: gene therapy   tumor targeting   
 

   

  

Also of Interest...
97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
99-158 Plasmid DNA vectors that integrate into host chromosomal DNA in vivo [Sleeping Beauty]
00-003 Altered recombinases for genome modification ("Shuffled" recombinases)

Recently Viewed...
S11-366 Mesenchymal stem cells as targeted-delivery vehicles for image-guided cancer treatment